Page last updated: 2024-12-06
andolast
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
andolast: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 65970 |
| CHEMBL ID | 119549 |
| SCHEMBL ID | 166170 |
| MeSH ID | M0409253 |
Synonyms (25)
| Synonym |
|---|
| 132640-22-3 |
| andolast |
| 4-(2h-tetrazol-5-yl)-n-[4-(2h-tetrazol-5-yl)phenyl]benzamide |
| CHEMBL119549 |
| cr2039 |
| andolast [inn] |
| benzamide, 4-(1h-tetrazol-5-yl)-n-(4-(1h-tetrazol-5-yl)phenyl)- |
| 6513m33209 , |
| 4,4'-di-1h-tetrazol-5-ylbenzanilide |
| cr 2039 |
| unii-6513m33209 |
| cr-2039 |
| 4-(1h-tetrazol-5-yl)-n-(4-(1h-tetrazol-5-yl)phenyl)benzamide |
| SCHEMBL166170 |
| DTXSID80157682 |
| cr 2039; dizolast |
| SB18787 |
| Q27263813 |
| andolast (free base) |
| MS-25019 |
| HY-106358 |
| CS-0025647 |
| andolast free base |
| benzamide, 4-(2h-tetrazol-5-yl)-n-[4-(2h-tetrazol-5-yl)phenyl]- |
| AKOS040747818 |
Research Excerpts
Overview
Andolast is a new airway specific anti-inflammatory agent.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Andolast is a new airway specific anti-inflammatory agent. " | ( Efficacy of Andolast in Mild to Moderate Asthma: A Randomized, Controlled, Double-Blind Multicenter Study (The Andast Trial). Arshad, SH; D Amato, M; Giacovelli, G; Holgate, ST; Malerba, M; Radaeli, A; Rovati, L, 2015) | 2.24 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic analysis was carried out using standard non-compartmental methods." | ( Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. Arshad, SH; D'Amato, M; Holgate, ST; Makovec, F; Persiani, S; Rovati, LC, 2001) | 0.63 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID182638 | Compound was evaluated for cytoprotective activity against sodium chloride-induced gastric lesions in male conscious rats | 1992 | Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20 | Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives. |
| AID182634 | Compound was evaluated for cytoprotective activity against acetic acid-induced gastric lesions in male conscious rats | 1992 | Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20 | Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives. |
| AID182637 | Compound was evaluated for cytoprotective activity against glucose-induced gastric lesions in male conscious rats | 1992 | Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20 | Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives. |
| AID179611 | Antiallergic activity against rat passive cutaneous anaphylaxis (PCA) reaction induced by 25 mg/kg of ovalbumin given iv(bolus) | 1992 | Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20 | Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives. |
| AID182635 | Cytoprotective activity against ethanol-induced gastric lesions in male conscious rats | 1992 | Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20 | Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.70
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.70) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||